|
1 Williams CS, Mann M, DuBois RN, et al. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 1999, 18(55)：7908–7916.
|
|
2 Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmac Sci, 2003, 24(2)：96–102.
|
|
3 Landen CN, Mathur SP, Richardson MS, et al. Expression of cyclooxygenase–2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol, 2003, 188(5)：1174–1176.
|
|
4 Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase–2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol, 2002, 20(4)：973–981.
|
|
5 Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol, 2002, 160(3)：893–903.
|
|
6 Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase–2. Semin Oncol, 1999, 26(5)：499–504.
|
|
7 Wu AW, Gu J, Li ZF, et al. COX–2 expression and tumor angiogenesis in colorectal cancer. World J Gastroenterol, 2004, 10(16)：2323–2326.
|
|
8 Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA, 2004, 291(20)：2433–2440.
|
|
9 Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase–2 levels in patients with gastric carcinoma. Cancer, 2001, 91(10)：1876–1881.
|
|
10 Umar A, Viner JL, Anderson WF, et al. Develonpment of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol, 2003, 26(4)：S48–57.
|
|
11 Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res, 2000, 60(16)：4629–4637.
|
|
12 Fujiwaki R, Iida K, Kanasaki H, et al. Cyclooxygenase–2 expression in endometrial cancer：Correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol, 2002, 33(2)：213–219.
|
|
13 Toyoki H, Fujimoto J, Sato E, et al. Clinical implications of expression of cyclooxygenase–2 related to angiogenesis in uterine endometrial cancers. Ann Oncol, 2005, 16(1)：51–55.
|
|
14 Moorman PG, Grubber JM, Millikan RC, et al. Association between non–steroidal anti–inflammatory drugs(NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control, 2003, 14(10)：915–922.
|
|
15 Nasir A, Boulware D, Kaiser HE, et al. Cyclooxygenase–2(COX–2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo, 2007, 21(1)：35–43.
|
|
16 Tong BJ, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase–2 and peroxisome proliferator–activated receptor–delta in human endometrial adenocarcinoma. Neoplasia, 2000, 2(6)：483–490.
|
|
17 Erkanli S, Bolat F, Kayaselcuk F, et al. COX–2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol, 2007, 104(2)：320–325.
|
|
18 Boldarian NA, Pozharisskii KM, Vinokurov VL, et al. Prognostic significance of cyclooxygenase(COX–1 and COX–2) expression in endometrial carcinoma(clinical and immunohistochemical study). Vopr Onkol, 2008, 54(1)：40–46.
|
|
19 Ferrandina G, Legge F, Ranelletti RO, et al. Cyclooxygenase–2 expression in endometrial carcinoma：Correlation with clinicopathologic parameters and clinical outcome. Cancer, 2002, 95(4)：801–807.
|
|
20 Cao QJ, Einstein MH, Anderson PS, et al. Expression of COX–2, Ki–67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol, 2002, 21(2)：147–154.
|
|
21 Orejuela FJ, Ramondetta LM, Smith J, et al. Estrogen and progesterone receptors and cyclooxygenase–2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol, 2005, 97(2)：483–488.
|
|
22 Fujiwaki R, Hata K, Iida K, et al. Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer. Gynecol Oncol, 1998, 68(3)：247–252.
|
|
23 Sugimoto T, Koizumi T, Sudo T, et al. Correlative expression of cyclooxygenase–1(Cox–1) and human epidermal growth factor receptor type–2(Her–2) in endometrial cancer. Kobe J Med Sci, 2007, 53(5)：177–187.
|
|
24 Lambropoulou M, Alexiadis G, Limberis V, et al. Clinicopathologic and prognostic significance of cyclooxygenase–2 expression in endometrial carcinoma. Histol Histophthol, 2005, 20(3)：753–759.
|
|
25 Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase–2(COX–2) and aromatase expression in human endometrial cancer: Tissue microarray analysis. Am J Obstet Gynecol, 2005, 192(4)：1262–1271.
|
|
26 Hwang D, Scollard D, Byme J, et al. Expression of cyclooxygenase–1 and cyclooxygenase–2 in human breast cancer. J Natl Cancer Res, 1998, 90(6)：455–460.
|
|
27 Yoshinura R, Sano H, Masuda C, et al. Expression of cyclooxygenase–2 in prostate carcinoma. Cancer, 2000, 89(3)：589–596.
|
|
28 Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase–2 protein in human gastric carcinoma. Clin Cancer Res, 2000, 6(2)：519–525.
|
|
29 Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase–2 expression in stage ⅠB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol, 2000, 76(3)：320–325.
|
|
30 Ozel E, Pestereli HE, Simsek T, et al. Expression of cyclooxygenase–2 and inducible nitric oxide synthase in ovarian surface epithelial carcinoma：Is there any correlation with angiogenesis or clinicopathogic parameters? Int J Gynecol Cancer, 2006, 16(2)：549–555.
|
|
31 Cramer DW, Harlow BL, Titus–Ernstoff L, et al. Over–the–counter analgesics and risk of ovarian cancer. Lancet，1998, 351(9906)：104–107.
|